Background: Premature ejaculation (PE) is a common sexual dysfunction that harms both sex partners.

Aim: To evaluate the safety, efficacy and impact on sexual satisfaction scores of the combined use of tramadol HCl and sildenafil citrate for the treatment of PE.

Methods: One hundred and sixty otherwise healthy males complaining of PE (primary/secondary) were enrolled in this randomized, double-blind, placebo-controlled study. Only 155 patients (age range 22-48 years) completed the study. Of them, 81 patients had primary PE, and 74 had secondary PE. The comparative groups included the placebo group ( = 34), sildenafil citrate 50 mg group ( = 39), tramadol HCl 100 mg group ( = 40), and the combination therapy group ( = 42). The treatment duration for all groups was 10 weeks.

Outcomes: This combination is safe and effective.

Results: Five patients discontinued the study, all from the placebo group, due to a lack of improvement over the treatment course. No significant differences were reported between groups before treatment as regards Intravaginal ejaculatory Latency Time (), satisfaction score (), age (), or duration of marriage (). There was a significant improvement in IELT after treatment with a placebo (), associated with an insignificant improvement in satisfaction score (). In the other three groups, there was a significant improvement in IELT after treatment ( for all), which coincided with a significant improvement in satisfaction scores in all three groups ( for all).

Clinical Implications: We recommend this combination in the treatment of premature ejaculation.

Strengths: It is a prospective randomized double-blind placebo-controlled clinical trial.

Limitations: Limited number of participants.

Conclusion: Combined therapy of PE, whether primary or secondary, with sildenafil citrate 50 mg and tramadol HCl 100 mg is safe and effective; and its therapeutic effect is superior to the utilization of either agent alone.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10929672PMC
http://dx.doi.org/10.1080/20905998.2023.2287869DOI Listing

Publication Analysis

Top Keywords

sildenafil citrate
16
tramadol hcl
12
treatment
8
treatment premature
8
premature ejaculation
8
satisfaction scores
8
randomized double-blind
8
double-blind placebo-controlled
8
primary secondary
8
placebo group
8

Similar Publications

Repurposing of phosphodiesterase-5 inhibitor sildenafil as a therapeutic agent to prevent gastric cancer growth through suppressing c-MYC stability for IL-6 transcription.

Commun Biol

January 2025

Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Phosphodiesterase-5 (PDE5) inhibitors have shown promise as anti-cancer agents in malignancies. However, their specific effects on gastric cancer (GC) and the underlying mechanisms remain elusive. Our aim was to investigate this by combining evidence from population-based studies with data obtained from in vivo and in vitro experiments.

View Article and Find Full Text PDF

The present work focuses on the production of sildenafil co-evaporates loaded emulgels as topical dosage forms for the treatment of premature ejaculation and erectile dysfunction. Topical administration of sildenafil citrate (SILD) co-evaporates is expected to improve the bioavailability profile of the drug and to avoid the severe side effects accompanying the traditional SILD dosage forms, especially for prohibited cardiovascular cases. Firstly, the solubility of SILD was improved via solid dispersion via co-evaporation technique using PEG-5KDa and PVP-K90 as hydrophilic carriers.

View Article and Find Full Text PDF

Orodispersible film (ODF) is one of the novel formulations that disintegrate rapidly in the mouth without the requisite for water compared to other conventional oral solid dosage formulations. This delivery system serves as a convenient mode of administration, especially in patients who have dysphagia and fluid restriction, being beneficial to pediatric, geriatric, and bedridden patients. A novel sildenafil ODF containing sildenafil citrate is formulated to be used in patients with erectile dysfunction (ED).

View Article and Find Full Text PDF

The anti ulcerogenic effect of sildenafil and moringa on ulcers in rats.

Tissue Cell

December 2024

Department of Pharmacology, College of Medicine,University of Baghdad, Iraq; Department of Pharmacology, College of Medicine, University of Baghdad, Iraq. Electronic address:

Article Synopsis
  • Moringa and Sildenafil oleifera (MO) may protect against gastric ulcers caused by medication in rats.
  • The study tested various groups of rats with one group receiving the ulcer-inducing drug indomethacin, and some receiving the protective effects of either Sildenafil, Moringa, or both beforehand.
  • Results showed that Sildenafil and Moringa effectively reduced ulcer severity and inflammation markers, indicating their potential as gastroprotective agents.
View Article and Find Full Text PDF

Paper-Based Aptasensor Assay for Detection of Food Adulterant Sildenafil.

Biosensors (Basel)

December 2024

Department of Medical Biology, School of Medicine, Atilim University, Ankara 06830, Turkey.

Sildenafil is used to treat erectile dysfunction and pulmonary arterial hypertension but is often illicitly added to energy drinks and chocolates. This study introduces a lateral flow strip test using aptamers specific to sildenafil for detecting its illegal presence in food. The process involved using graphene oxide SELEX to identify high-affinity aptamers, which were then converted into molecular gate structures on mesoporous silica nanoparticles, creating a unique signaling system.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!